Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697148 | 0.85 | BRD4 (0.45) | L3MBTL1KDM4ECYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL27185561 | 0.78 | CA12 (0.37) | L3MBTL1KDM4ECYP4F2CYP4A11KDM6B | |
| SCHEMBL29784529 | 0.78 | CA12 (0.37) | L3MBTL1KDM4ECYP4F2CYP4A11KDM6B | |
| SCHEMBL30036150 | 0.78 | L3MBTL1 (0.55) | L3MBTL1NPSR1KDM4ECYP4F2CYP4A11 | |
| SCHEMBL1979301 | 0.78 | L3MBTL1 (0.55) | L3MBTL1NPSR1KDM4ECYP4F2CYP4A11 | |
| SCHEMBL30615231 | 0.77 | L3MBTL1 (0.46) | L3MBTL1NPSR1DYRK1AKDM4EASPH | |
| SCHEMBL26613729 | 0.77 | L3MBTL1 (0.46) | L3MBTL1NPSR1DYRK1AKDM4EASPH | |
| SCHEMBL29918922 | 0.76 | L3MBTL1 (0.45) | L3MBTL1NPSR1DYRK1AKDM4EASPH | |
| SCHEMBL2067513 | 0.76 | L3MBTL1 (0.45) | L3MBTL1NPSR1DYRK1AKDM4EASPH | |
| SCHEMBL25405881 | 0.74 | L3MBTL1 (0.44) | L3MBTL1NPSR1DYRK1AKDM4EASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701735-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | Nested Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4514471-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119487021-A | Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK) | 内斯特治疗公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024226579-A9 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | NESTED THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024226579-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | NESTED THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023211812-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211812-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK1, MAP3K1, MAPK3 | L3MBTL1 4511/4885NPSR1 4045/4885DYRK1A 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.